This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Theratechnologies’ Ibalizumab Study: A Potential Game-Changer for Multidrug-Resistant HIV

Tipranks - Tipranks - Tue Aug 12, 2025

Theratechnologies ((THTX)), Theratechnologies (TH) ((TSE:TH)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Study Overview: Theratechnologies is conducting a study titled ‘A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab.’ The study aims to evaluate the long-term efficacy, safety, and durability of ibalizumab, a treatment for multidrug-resistant HIV, by comparing patient outcomes with and without the drug. This research is significant as it seeks to provide insights into the real-world effectiveness of ibalizumab, potentially impacting treatment strategies for patients with limited options.

Intervention/Treatment: The study tests ibalizumab, a CD4-directed post-attachment HIV-1 inhibitor. It is used in combination with other antiretrovirals to treat heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Study Design: This observational study follows a cohort model with a prospective time perspective. It includes two groups: patients not receiving ibalizumab and those on ibalizumab treatment. The primary purpose is to assess the drug’s long-term efficacy and safety.

Study Timeline: The study began on March 22, 2022, and is currently recruiting participants. The last update was submitted on August 8, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.

Market Implications: The ongoing study could influence Theratechnologies’ stock performance by providing evidence of ibalizumab’s effectiveness, potentially boosting investor confidence. As the study progresses, it may also impact the competitive landscape in the HIV treatment market, where advancements in drug efficacy are highly valued.

The study is ongoing, with further details available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Trending Articles

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).